UMIN ID: UMIN000001922
Registered date:01/05/2009
The exploratory analysis for the efficacy and safety of Rikkunshito for upper gastrointestinal symptoms in the patients with functional dyspepsia
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | Functional dyspepsia |
Date of first enrollment | 2008/03/01 |
Target sample size | 30 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | Rikkunshito 7.5g per day before meal 4 weeks Domperidone 30mg per day before meal 4 weeks |
Outcome(s)
Primary Outcome | The upper gastrointestinal symptoms at 2 and 4 weeks after drug administartion |
---|---|
Secondary Outcome | The change of the level in the hormone related to appetite at 2 and 4 weeks after drug administartion |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | 80years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | The patients (1)after removal of their stomach (2)with heart failure or severe inflammation (3)with disorder in liver, gallbladder, or pancreas (4)with pregnancy, or breast-feeding now (5)with astrointestinal bleeding, mechanical ileus, perforation in gastrointestine (6)taking prohibited drug during trial (7) impossible to take a drug per oral (8)taking herbal medicine during trial (9)who are unsuitable judged by the responsible person |
Related Information
Primary Sponsor | Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | TSUMURA Co. |
Secondary ID(s) |
Contact
public contact | |
Name | MAKOTO ARAI |
Address | Inohana 1-8-1, Chuo-ku, Chiba-City, Japan Japan |
Telephone | |
Affiliation | Graduate School of Medicine, Medicine and Clinical Oncology |
scientific contact | |
Name | MAKOTO ARAI |
Address | Inohana 1-8-1, Chuo-ku, Chiba-City, Japan Japan |
Telephone | 043-226-2083 |
Affiliation | Graduate School of Medicine, Chiba University Medicine and Clinical Oncology |